title: Differential expression of p42.3 in low- and high-grade gliomas.
abstract: BACKGROUND
  Malignant gliomas are the most common form of primary malignant brain tumor. It has recently been suggested that genetic changes are involved in the progression of malignant gliomas. In previous studies, a novel gene, p42.3, was characterized as a tumor-specific gene that encodes a mitosis phase-dependent expression protein which is expressed in gastric cancer, but not in matched normal tissues.
  
  
  METHODS
  In a series of 200 human brain gliomas and 13 normal tissues, we performed RT-PCR and mRNA in situ hybridization for analysis of p42.3 gene expression in gliomas, including astrocytoma (grade 2), oligoastrocytomas (grade 2), anaplastic oligoastrocytomas (grade 3), glioblastomas (grade 4) and normal tissues. Also, the mRNA expression was detected in gliomas by in situ hybridization. After producing polyclonal antibody to p42.3, we further tested p42.3 protein expression in astrocytomas and glioblastomas by immunohistochemistry and Western blot analysis.
  
  
  RESULTS
  Our results demonstrated that overexpression of the p42.3 gene is detected in gliomas, but not in normal brain tissues. Importantly, p42.3 mRNA expression is correlated with the pathological features of gliomas. In addition, p42.3 protein is expressed in both the cytoplasm and the nucleus in astrocytomas, whereas this protein appeared in the cytoplasm in glioblastomas.
  
  
  CONCLUSIONS
  These results indicate that p42.3 might be involved in carcinogenesis as a potential molecular marker for malignant gliomas.
authors.forename: Weiqing
authors.initials: W
authors.lastname: Wan
authors.forename: Xiaoqing
authors.initials: X
authors.lastname: Xu
authors.forename: Guijun
authors.initials: G
authors.lastname: Jia
authors.forename: Wenmei
authors.initials: W
authors.lastname: Li
authors.forename: Junmei
authors.initials: J
authors.lastname: Wang
authors.forename: Tong
authors.initials: T
authors.lastname: Ren
authors.forename: Zhen
authors.initials: Z
authors.lastname: Wu
authors.forename: Junting
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Neurosurgery, Beijing Tiantan Hospital Capital Medical University, No,6 Tiantan Xili, Dongcheng District, 100050 Beijing, People's Republic of China. zlwtt@aliyun.com.
authors.forename: Liwei
authors.initials: L
authors.lastname: Zhang
authors.forename: Youyong
authors.initials: Y
authors.lastname: Lu
mesh_terms: D000818:Animals; D000917:Antibody Formation; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D015152:Blotting, Northern; D015153:Blotting, Western; D001921:Brain / Q000378:metabolism*; D001932:Brain Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D018797:Cell Cycle Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D017403:In Situ Hybridization; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009687:Nuclear Proteins; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D011817:Rabbits; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D009687:Nuclear Proteins; D012333:RNA, Messenger; C000607889:SAPCD2 protein, human